## Hendrik Neubert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6451745/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. Gene Therapy, 2022, 29, 608-615.	2.3	11
2	Application of Immunoaffinity Mass Spectrometry (IA-MS) for Protein Biomarker Quantification. Methods in Molecular Biology, 2022, 2466, 111-119.	0.4	0
3	2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome ( <u>Part 1</u> – Recommendations) Tj ETC	Qq1 1 0.7 0.6	84314 rg8 24
4	A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs. Frontiers in Bioinformatics, 2021, 1, .	1.0	4
5	Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision. Clinical Chemistry, 2020, 66, 282-301.	1.5	69
6	A Physiologicallyâ€Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From <i>In Vitro</i> Data. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 738-747.	1.3	34
7	Human FcRn Tissue Expression Profile and Half-Life in PBMCs. Biomolecules, 2019, 9, 373.	1.8	27
8	Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations. Bioanalysis, 2019, 11, 2011-2024.	0.6	15
9	Measuring the Turnover Rate of Clinically Important Plasma Proteins using an Automated SISCAPA Workflow. Clinical Chemistry, 2019, 65, 492-494.	1.5	11
10	Protein Turnover Measurements in Human Serum by Serial Immunoaffinity LC-MS/MS. Clinical Chemistry, 2018, 64, 279-288.	1.5	15
11	Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 77-86.	0.6	23
12	Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease. MAbs, 2018, 10, 62-70.	2.6	4
13	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq1 1	007.84314	r <b>g8</b> T /Overl
14	Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities. Scientific Reports, 2018, 8, 7781.	1.6	30
15	Clinical chemoproteomics—Opportunities and obstacles. Science Translational Medicine, 2017, 9, .	5.8	21
16	2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) Tj ETQq0	0 0 rgBT 0.6	/Overlock 1 32
17	Large-scale implementation of sequential protein and peptide immunoaffinity enrichment LC/nanoLC–MS/MS for human β-nerve growth factor. Bioanalysis, 2016, 8, 753-764.	0.6	21

18Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by<br/>Online Peptide Immuno-Affinity LC-HRMS. Analytical Chemistry, 2016, 88, 4239-4247.3.233

Hendrik Neubert

#	Article	IF	CITATIONS
19	Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs, 2016, 8, 1064-1078.	2.6	72
20	Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs, 2016, 8, 848-853.	2.6	23
21	Quantification of protein biomarkers in tissues: new capabilities with pellet digestion peptide immunoaffinity LC–MS/MS. Bioanalysis, 2016, 8, 1551-1555.	0.6	18
22	Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS. Proteomics - Clinical Applications, 2016, 10, 597-604.	0.8	17
23	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays. Clinical Chemistry, 2016, 62, 48-69.	1.5	187
24	Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease. PLoS ONE, 2016, 11, e0155368.	1.1	24
25	Quantification of Protein Biomarkers Using Liquid Chromatography Tandem Mass Spectrometry. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 87-98.	0.2	0
26	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 –) Tj ETQ	q0.0.0 rgB 0.6	T /Overlock 47
27	Mass Cytometry: A Highly Multiplexed Single-Cell Technology for Advancing Drug Development. Drug Metabolism and Disposition, 2015, 43, 227-233.	1.7	71
28	Quantification of biotherapeutic targets: new opportunities with immunoaffinity LC–MS/MS. Bioanalysis, 2014, 6, 1731-1733.	0.6	23
29	Serum β-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys. NeuroReport, 2014, 25, 829-832.	0.6	5
30	Highly Specific and Sensitive Measurements of Human and Monkey Interleukin 21 Using Sequential Protein and Tryptic Peptide Immunoaffinity LC-MS/MS. Analytical Chemistry, 2013, 85, 5522-5529.	3.2	96
31	Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human β-Nerve Growth Factor. Analytical Chemistry, 2013, 85, 1719-1726.	3.2	117
32	Clinical Pharmacokinetic Assessment of an Anti-MAdCAM Monoclonal Antibody Therapeutic by LC-MS/MS. Analytical Chemistry, 2012, 84, 5959-5967.	3.2	81
33	Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD. Bioanalysis, 2012, 4, 2589-2604.	0.6	34
34	An immunoaffinity liquid chromatography–tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Analytical Biochemistry, 2010, 399, 202-210.	1.1	68
35	Online High-Flow Peptide Immunoaffinity Enrichment and Nanoflow LC-MS/MS: Assay Development for Total Salivary Pepsin/Pepsinogen. Clinical Chemistry, 2010, 56, 1413-1423.	1.5	92

<sup>36</sup> Online capillary weak cation exchange enrichment hyphenated to nanospray mass spectrometry for quantitation of a basic pegvisomant derived peptide. Journal of Chromatography A, 2009, 1216, 6151-6154. 1.8 11

#	Article	IF	CITATIONS
37	Label-Free Detection of Differential Protein Expression by LC/MALDI Mass Spectrometry. Journal of Proteome Research, 2008, 7, 2270-2279.	1.8	100
38	Assessing Immunogenicity in the Presence of Excess Protein Therapeutic Using Immunoprecipitation and Quantitative Mass Spectrometry. Analytical Chemistry, 2008, 80, 6907-6914.	3.2	59